A longitudinal analysis of PEGASYS [peginterferon alfa-2a] on HBV [hepatitis B virus] -specific T cell responses in patients with HBeAg-negative chronic hepatitis B Infection - immunology sub-study of ML18253
Phase of Trial: Phase III
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Roche
- 18 Nov 2009 Status changed from active, no longer recruiting to completed as reported by Roche record.
- 10 Jan 2008 Roche reported as trial sponsor.
- 24 Apr 2007 New trial record.